As of the most recent check, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock was up 10.98% to trade at $13.99, continuing its upward trend. Recursion’s stock has increased in response to a major disclosure about a new database project. Recursion (RXRX) showcased LOWE (Large Language Model-Orchestrated Workflow Engine) in action.
LOWE is a new program developed by RXRX that uses a natural language interface to carry out intricate drug discovery activities. It can coordinate studies utilizing Recursion’s automated wet laboratories and is driven by Recursion’s exclusive biological and chemical data, releasing the full potential of the Recursion Operating System in a user-friendly application.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Over the last ten years, Recursion has worked to compile one of the largest biological and chemical databases in the world. In addition, the company has developed automated wet-lab and dry-lab technologies that enable scientists to swiftly decipher biology and identify and progress promising initiatives.
Large Language Models have learned to utilize many of Recursion’s tools and data for the first time, far more easily and scalable than an experienced scientist would. LOWE is a step toward the creation of autonomous “AI scientists” for therapeutic research and offers an intriguing peek at what RXRX believes the future of drug discovery will hold.
During Recursion’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Co-founder and CEO of Recursion Chris Gibson revealed LOWE. Recursion and NVIDIA will co-host an invite-only event on Wednesday, January 10, with further LOWE software demonstrations and an amazing roster of speakers.
LOWE was created by Recursion’s AI research engine, Valence Labs, after Valence Discovery was acquired by Recursion in May 2023. The creation of Foundation models that faithfully depict or recreate the biological and chemical realms of drug discovery is just one of the many projects Valence is leading to improve the future of AI-enabled scientific discovery.
While reasoning and orchestration systems like LOWE can plan and carry out experiments for hypothesis testing, inference engines and active learners are used to develop hypotheses and learn from the findings.
